Alzheimer's Disease Clinical Trials in Georgia

26 recruiting studies across 1 city

Browse by City

All Trials in Georgia

Phase

Trial	Phase	Sponsor	Dist.
Georgia Memory Net Anti-Amyloid Monoclonal Antibody Registry	—	Emory University	<1 mi
Longitudinal Early-onset Alzheimer's Disease Study Protocol	—	Indiana University	<1 mi
Alzheimer's Disease Neuroimaging Initiative 3 (ADNI3)	—	University of Southern California	<1 mi
A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation	Phase 2/3	Washington University School of Medicine	<1 mi
Partnered Rhythmic Rehabilitation in Prodromal Alzheimer's Disease	N/A	Emory University	<1 mi
Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants With Alzheimer's Disease	Phase 2	Celgene	<1 mi
A Study of a Potential Disease Modifying Treatment in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation	Phase 2/3	Washington University School of Medicine	<1 mi
A Study of LY4006895 in Healthy Participants With Early Symptomatic Alzheimer's Disease (AD)	Phase 1	Eli Lilly and Company	<1 mi
A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)	Phase 3	Karuna Therapeutics	<1 mi
Locomotion Adaptation Deficits in Older Adults With Mild Cognitive Impairment and Alzheimers Disease	N/A	Emory University	<1 mi
DECIDE: Dyads and Families	N/A	Emory University	<1 mi
A Trial to Evaluate the Safety and Efficacy of Benfotiamine in Patients With Early Alzheimer's Disease (BenfoTeam)	Phase 2	Alzheimer's Disease Cooperative Study (ADCS)	<1 mi
Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)	Phase 3	Karuna Therapeutics	<1 mi
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-2)	Phase 3	Bristol-Myers Squibb	<1 mi
Inspiring Seniors Towards Exercise Promotion to Protect Cognition	N/A	Emory University	<1 mi
Electroconvulsive Therapy (ECT) for Agitation in Dementia (AD)	N/A	Brent Forester	<1 mi
Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant	Phase 3	Eidos Therapeutics, a BridgeBio company	<1 mi
Gamma Sensory Flicker for Parkinson's Disease Patients With Freezing of Gait	N/A	Emory University	<1 mi
A First-In-Human Study of LY3954068 in Participants With Early Symptomatic Alzheimer's Disease	Phase 1	Eli Lilly and Company	6 mi
Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies	Phase 3	Hoffmann-La Roche	6 mi
A Double-blind Dual Study Assessing Safety and Efficacy of Buntanetap in Participants With Early AD	Phase 3	Annovis Bio Inc.	6 mi
A Phase Ia/Ib, First-in-human (FIH) Study for Safety, Tolerability, Pharmacokinetics (PK), and Clinical Activity Evaluation of ADEL-Y01	Phase 1	Alzheimer's Disease Expert Lab (ADEL), Inc.	6 mi
A Clinical Study of MK-2214 in People With Early Alzheimer's Disease (MK-2214-004)	Phase 2	Merck Sharp & Dohme LLC	6 mi
A Study of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease	Phase 3	Hoffmann-La Roche	6 mi
A Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease	Phase 3	Hoffmann-La Roche	6 mi
A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease	Phase 3	Bristol-Myers Squibb	50 mi

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.